Abide Therapeutics Appoints Donald Hertzog as Vice President, Early Lead Identification

SAN DIEGO, Sept. 8, 2015 /PRNewswire/ — Abide Therapeutics announced today the appointment of Donald Hertzog, Ph.D., as Vice President, Early Lead Identification. Dr. Hertzog was previously the site head and director for GlaxoSmithKline’s Molecular Discovery Research Department of Medicinal Chemistry in Research Triangle Park, North Carolina. Dr. Hertzog has more than 20 years of experience in drug discovery and development in …

Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator

SAN DIEGO, July 7, 2015 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing of the first subject in a Phase 1a clinical study of ABX-1431, a first-in-class, investigational endocannabinoid system modulator. ABX-1431 was discovered with Abide’s proprietary technology platform, which finds new small molecule drug candidates that target serine hydrolases, a large …

Nature Chemical Biology Recognizes Breakthrough Research Publication as one of its “Greatest Hits”

SAN DIEGO, June 4, 2015 – Breakthrough Research Formed the Foundation for Abide’s Technology Nature Chemical Biology celebrated its 10th anniversary with a special issue dedicated to the “Greatest Hits”—the best papers published by the journal to date. The 2009 paper named “Best Cartography” was authored by Abide co-founder Benjamin Cravatt, PhD, professor and chair of the Department of Chemical Physiology …

Abide Therapeutics Announces a Collaborative Agreement with the University of Oxford

SAN DIEGO, November 4, 2014 /PRNewswire/ — Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets. Under the three-year agreement, Abide …

Abide in the Top 10 of Life Science Startups to Watch in the US

SAN DIEGO, October 27, 2014 – Abide was recognized as #9 on BioSpace’s list of Top 30 Life Science Startups to Watch in the U.S. The list was ranked cumulatively based on points awarded in five categories: finance, collaborations, pipeline, sales, and editorial. 9. Abide Therapeutics Points: 17 Founded: 2011 Location: San Diego, Calif. Notable: – In 2013, Abide entered …

Abide Therapeutics Appoints Nancy Thornberry to Board of Directors

SAN DIEGO, July 29, 2014 /PRNewswire/ — Abide Therapeutics announced today the appointment of Nancy Thornberry to its board of directors. Thornberry was previously senior vice president and franchise head, Diabetes and Endocrinology for Merck & Co. Inc., where she led discovery, clinical research, strategy and overall pipeline management in diabetes, osteoporosis, fertility and contraception. Thornberry, a distinguished pharmaceutical scientist, …

Abide’s Co-founders and SAB Members Elected to the National Academy of Sciences

SAN DIEGO, May 5, 2014 – Abide Therapeutics congratulates the Company’s co-founders and scientific advisory board (SAB) members, Drs. Benjamin Cravatt and Dale Boger, and SAB member, Dr. Gregory Fu, for their election to the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research. Abide is honored by this recognition of their founders and SAB …

Abide Therapeutics Announces Strategic Drug Discovery Collaboration with Celgene Corporation to Advance Treatment Paradigm for Patients with Immune Disorders

SAN DIEGO and PRINCETON, N.J, Feb. 28, 2014 — Abide Therapeutics today announced it has entered into a strategic collaboration with Celgene Corporation to discover and develop new drugs in inflammation and immunology. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology. Under the terms of the agreement, …

Abide Therapeutics Appoints Dr. Gary O’Neill as Vice President of Biology

SAN DIEGO, Oct. 29, 2013 – Abide Therapeutics announces today that Gary O’Neill, Ph.D., has joined Abide Therapeutics as vice president of biology and member of the senior management team. Dr. O’Neill was previously discovery site head and vice president at Merck Research Laboratories in Boston, where he was responsible for Merck’s preclinical drug discovery programs in respiratory, immunology and …